glp-1 drugs pharmaceutical companies partnerships 2025 2.0: Where the Next Wave of Value Will Be Created From Lab to Last Mile:

In vitro experiments provided a relative understanding of the binding affinities, revealing that compound 38 displayed similar DPP-4 inhibition in the nM range compared to the reference medication, Vildagliptin

Indeed, acute elevated peripheral insulin levels may increase insulin in cerebrospinal fluid, whereas, chronic peripheral hyperinsulinemia (such as insulin resistance or T2DM) may downregulate insulin receptors of the BBB, impair brain insulin uptake, and ultimately lead to learning, memory, and cognitive deficits (52)

There was also an association with pre-operative gastrointestinal symptoms (e.g., nausea, vomiting, abdominal pain, bloating) and the degree of residual gastric contents

A dual GCGR-GLP-1R co-agonist formulated by introducing key GCG amino acid residues into the exendin-4 structure produced a robust inhibition of food intake and weight loss to a greater extent than similar doses of liraglutide in mice and monkeys with diet-induced obesity [49]

Gerti Tashko, MD Dr